Articles related to LEUKEMIA

Patients with newly diagnosed acute myeloid leukemia (AML) have had better results thanks to alterations to cytarabine/anthracycline-based intense chemotherapy, including the addition of high-dose cytarabine and adjustments to the dosage schedule or type of anthracycline.

Overall survival was longer and the rate of remission was higher among patients who received azacitidine (Vidaza) with venetoclax (Venclexta) than among those who received azacitidine alone in previously untreated patients who were ineligible for intense chemotherapy. Compared to the control group, the venetoclax-azacitidine group had a greater incidence of febrile neutropenia.

Event-free survival (EFS) was significantly increased with enasidenib compared to conventional care regimens (CCR) in this open-label, randomized, phase 3 trial; overall survival (OS) was complicated by early dropout and usage of later AML medications. The older R/R mutant-IDH2 AML group received notable morphologic and hematologic responses from enasidenib as opposed to CCR.

In this multinational, phase 3, head-to-head trial (ALPINE), patients who received zanubrutinib — a Bruton’s tyrosine kinase (BTK) inhibitor with greater specificity– rather than the BTK inhibitor ibrutinib, had significantly longer progression-free survival in individuals with relapsed or refractory CLL or SLL, and zanubrutinib was linked to fewer cardiac side events.

The decision to remove Lumoxiti from the US market was attributable to its extremely poor clinical uptake because there were other treatment choices available, according to AstraZeneca’s letter to healthcare professionals. Its limited uptake may also have been caused by the complicated administration, the requirement for toxicity prophylaxis, and the need for safety monitoring. The elimination has nothing to do with the drug’s efficacy or safety.

Today, it is possible to safely treat CML throughout pregnancy with little danger to the unborn child, as TKIs can now be safely administered during the later stages of pregnancy, according to new research. After beginning or continuing TKI therapy, a sizable majority of patients can be managed by observation alone, and disease control can be attained. IFN-α may be given in any trimester with little harm to the fetus if active treatment is necessary. Most essential, however, is a multidisciplinary strategy to offer clear and concise guidance to enable both the mother and the family to participate in the decision-making process.